

Mometasone Cream Formulation

Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone Cream Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil B-2220

Telephone : 551-430-6000

Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Eye irritation : Category 2A

Long-term (chronic) aquatic hazard : Category 2

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H319 Causes serious eye irritation.
H411 Toxic to aquatic life with long lasting effects.

Precautionary Statements :

Prevention:

P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear eye protection/ face protection.

Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P391 Collect spillage.

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5		≥ 50 -< 70
2-Methyl-2,4-pentanediol	107-41-5	Flammable liquids, Category 4 Acute toxicity (Oral), Category 5 Eye irritation, Category 2A	≥ 10 -< 20
Titanium dioxide	13463-67-7	Carcinogenicity (Inhalation), Category 2	≥ 1 -< 5
Mometasone	83919-23-7	Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Inhalation) (Immune system, Liver, Kidney, Skin), Category 2 Long-term (chronic) aquatic hazard, Category 1	$\geq 0,1$ -< 0,25

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes serious eye irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Vapors may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
2-Methyl-2,4-pentanediol	107-41-5	TWA (Vapor)	25 ppm	ACGIH
		STEL (Vapor)	50 ppm	ACGIH
		STEL (Inhalable fraction, Aerosol only)	10 mg/m ³	ACGIH

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

Titanium dioxide	13463-67-7	TWA	10 mg/m ³ (Titanium dioxide)	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : cream

Color : white to off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : > 93,3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapors may form explosive mixture with air.
Can react with strong oxidizing agents.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:**White mineral oil (petroleum):**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

2-Methyl-2,4-pentanediol:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6,82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3,3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No skin irritation

2-Methyl-2,4-pentanediol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No eye irritation

2-Methyl-2,4-pentanediol:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Titanium dioxide:

Species	:	Rabbit
Result	:	No eye irritation

Mometasone:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Test Type	:	Buehler Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	negative

2-Methyl-2,4-pentanediol:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Titanium dioxide:

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Skin contact
Species	:	Mouse
Result	:	negative

Mometasone:

Test Type	:	Maximization Test
Routes of exposure	:	Dermal
Species	:	Guinea pig
Assessment	:	Does not cause skin sensitization.
Result	:	negative
Remarks	:	The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat

Cell type: Liver cells

Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rat
 Application Route : Ingestion
 Exposure time : 24 Months
 Result : negative

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Mometasone:

Species : Rat
 Application Route : Inhalation
 Exposure time : 2 Years
 Dose : 0.067 mg/kg body weight
 Result : negative

Species : Mouse
 Application Route : Inhalation
 Exposure time : 19 Months
 Dose : 0.160 mg/kg body weight
 Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Effects on fertility : Test Type: One-generation reproduction toxicity study

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Species: Rat
Application Route: Skin contact
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

2-Methyl-2,4-pentanediol:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 421
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0,015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0,06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0,3 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Embryo-fetal toxicity.: LOAEL: 0,15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: LOAEL: 0,7 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Routes of exposure : inhalation (dust/mist/fume)
Target Organs : Immune system, Liver, Kidney, Skin
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****White mineral oil (petroleum):**

Species : Rat
LOAEL : 160 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Species : Rat
LOAEL : >= 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 4 Weeks
Method : OECD Test Guideline 412

2-Methyl-2,4-pentanediol:

Species : Rat
NOAEL : >= 450 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Mometasone Cream Formulation

Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

Method : OECD Test Guideline 408

Titanium dioxide:

Species : Rat
NOAEL : 24.000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 y

Mometasone:

Species : Rat
NOAEL : 0,005 mg/kg
LOAEL : 0,3 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0,5 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
NOAEL : 0,00013 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog
NOAEL : 0,0005 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Experience with human exposure**Components:****2-Methyl-2,4-pentanediol:**

Eye contact : Target Organs: Eyes
Symptoms: Irritation

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks : Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****White mineral oil (petroleum):**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 1.000 mg/l
Exposure time: 28 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1.000 mg/l
Exposure time: 21 d

2-Methyl-2,4-pentanediol:

Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8.510 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 2.800 mg/l
Exposure time: 48 h

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC: 200 mg/l
Exposure time: 10 d

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10.000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1.000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0,11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox- : NOEC (Pimephales promelas (fathead minnow)): 0,00014

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

icity)		mg/l
		Exposure time: 32 d
		Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,34 mg/l
		Exposure time: 21 d
		Method: OECD Test Guideline 211
		Remarks: No toxicity at the limit of solubility.
M-Factor (Chronic aquatic toxicity)	:	100
Toxicity to microorganisms	:	EC50: > 1.000 mg/l
		Exposure time: 3 h
		Test Type: Respiration inhibition
		Method: OECD Test Guideline 209
		Remarks: No toxicity at the limit of solubility.
		NOEC: 1.000 mg/l
		Exposure time: 3 h
		Test Type: Respiration inhibition
		Method: OECD Test Guideline 209
		Remarks: No toxicity at the limit of solubility.

Persistence and degradability**Components:****White mineral oil (petroleum):**

Biodegradability	:	Result: Not readily biodegradable.
		Biodegradation: 31 %
		Exposure time: 28 d

2-Methyl-2,4-pentanediol:

Biodegradability	:	Result: Readily biodegradable.
		Biodegradation: 81 %
		Exposure time: 28 d
		Method: OECD Test Guideline 301F

Mometasone:

Biodegradability	:	Result: Not readily biodegradable.
		Biodegradation: 50 %
		Exposure time: 28 d
		Method: OECD Test Guideline 314

Stability in water	:	Hydrolysis: 50 %(12 d)
		Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****2-Methyl-2,4-pentanediol:**

Partition coefficient: n-	:	log Pow: 0
---------------------------	---	------------

Mometasone Cream Formulation

Version 5.2 Revision Date: 09.04.2021 SDS Number: 1688390-00011 Date of last issue: 10.10.2020
Date of first issue: 21.05.2017

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Mometasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Mometasone)
Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)

Group 2B: Possibly carcinogenic to humans
Titanium dioxide 13463-67-7

Brazil. List of chemicals controlled by the Federal Police : Not applicable

International Regulations**The ingredients of this product are reported in the following inventories:**

AICS : not determined
DSL : not determined
IECSC : not determined

SAFETY DATA SHEET



Mometasone Cream Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

SECTION 16. OTHER INFORMATION

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

ACGIH / STEL : Short-term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Mometasone Cream Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.2	09.04.2021	1688390-00011	Date of first issue: 21.05.2017

BR / Z8